Pivotal Study to Assess the Safety and Effectiveness of the iTind Device

Not Applicable

Completed

• Conditions: Benign Prostate Hyperplasia

• Registration Number: NCT02506465
• Lead Sponsor: Medi-Tate Ltd.

Brief Summary

The study objectives are to demonstrate the efficacy and safety of the Medi-Tate iTIND as compared to control group (catheter only).

Detailed Description

Medi-Tate i-Temporary Implantable Nitinol Device (iTind) is intended to treat subjects with symptomatic BPH.

A total of 150 subjects with symptomatic BPH will be enrolled into this study, according to eligibility criteria.

Study duration is 12 months and includes 7 visits: screening, screening follow up, implantation, retrieval, 6 weeks follow up, 3 months follow up and 12 months follow up.

iTind Device will be implanted for 5-7 days. Sham will be a routine Foley catheter procedure.

Study Timeline

• Study Start: 2015-07
• Study First Submitted: 2015-07-14
• Study First Submitted QC: 2015-07-22
• Study First Posted: 2015-07-23
• Primary Completion: 2018-10
• Study Completion: 2018-10
• Results First Submitted: 2021-12-19
• Results First Submitted QC: 2022-01-12
• Status Verified: 2022-02
• Results First Posted: 2022-02-08
• Last Update Submitted: 2022-02-16
• Last Update Posted: 2022-02-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 185

Inclusion Criteria

1. Subject signed informed consent form (ICF)
2. Age 50 and above
3. Male with symptomatic BPH.
4. IPSS symptom severity score ≥ 10
5. Peak urinary flow of < 12 ml/sec . Meeting the criterion on (2) two separate voiding trials , on a minimum voided volume of at least 125 cc for each voiding trial.
6. Prostate volume between 25 ml to 75 ml (assessed by ultrasound)
7. Blood CBC and biochemistry up to two weeks before screening demonstrating: Normal values of the PT, PTT and INR tests (anticoagulants should be stopped according to GCP)
8. Subject able to comply with the study protocol
9. Normal Urinalysis and urine culture

Exclusion Criteria

1. Cardiac arrhythmias, cardiac disease including congestive heart failure, uncontrolled diabetes mellitus, significant respiratory disease, or known immunosuppression;
2. Neurogenic bladder and/or sphincter abnormalities due to Parkinson's disease, multiple sclerosis, cerebral vascular accident, diabetes
3. A post void residual (PVR) volume > 250 ml measured by ultrasound or acute urinary retention
4. Compromised renal function (i.e., serum creatinine level > 1.8 mg/dl, or upper tract disease);
5. Confirmed or suspected bladder cancer;
6. Recent (within 3 months) cystolithiasis or hematuria;
7. Urethral strictures, bladder neck contracture, urinary bladder stones or other potentially confounding bladder pathology;
8. An active urinary tract infection.
9. Enrolled in another treatment trial for any disease within the past 30 days.
10. Previous colo- rectal surgery (other than hemorrhoidectomy) or history of rectal disease if the therapy may potentially cause injury to sites of previous rectal surgery, e.g., if a transrectal probe is used;
11. Previous pelvic irradiation, cryosurgery or radical pelvic surgery;
12. Previous prostate surgery, balloon dilatation, stent implantation, laser prostatectomy, hyperthermia, or any other invasive treatment to the prostate
13. History of prostatitis within the past 5 years.
14. Median lobe obstruction of the prostate.
15. Cancer that is not considered cured, except basal cell or squamous cell carcinoma of the skin (cured defined as no evidence of cancer within the past 5 years).
16. Any serious medical condition likely to impede successful completion of the study
17. Participating in any other investigational study for either drug or device which can influence collection of valid data under this study.
18. Subjects who are actively taking medications that affects urination and BPH symptoms not completing the required washout period.
19. Baseline PSA ≥ 10 ng/ml.
20. Positive DRE.
21. Baseline PSA between 2.5-10 ng/ml and free PSA < 25%, without a subsequent negative prostate biopsy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Month 3 Results in the IPSS Score in Both Arms.	3 months	Month 3 results in the IPSS Score in both arms IPSS - The International Prostate Symptom Score. Scale: minimum 0 (zero), maximum 35. Lower values are better.

Secondary Outcome Measures

Name	Time	Method
PVR	3 months	Month 3 results in PVR (post-void residual urine volume)
Qmax Measurement	3 months	Month 3 results in Qmax (maximum urinary flow rate)
IIEF Questionnaire	3 months	The International Index of Erectile Function score. Scale: minimum 6, maximum 75. Higher values are better. Month 3 results in IIEF.
SHIM	3 months	The Sexual Health Inventory for Men questionnaire. Scale: minimum 1, maximum 25. Higher values are better. Month 3 results in SHIM.

Trial Locations

Locations (13)

Clinical Research Center of Florida; 🇺🇸 Pompano Beach, Florida, United States

Chesapeake Urology Research Associates; 🇺🇸 Baltimore, Maryland, United States

Methodist Hospital; 🇺🇸 Brooklyn, New York, United States

Winthrop University; 🇺🇸 Garden City, New York, United States

St John's Episcopal; 🇺🇸 Lawrence, New York, United States

Integrated Medical Professionals; 🇺🇸 Long Island City, New York, United States

Manhattan Medical research; 🇺🇸 Manhattan, New York, United States

Weill cornell; 🇺🇸 Manhattan, New York, United States

Premier Urology Group; 🇺🇸 New York, New York, United States

Primier Medical Center; 🇺🇸 Poughkeepsie, New York, United States

Scroll for more (3 remaining)